

United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.usdlo.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/840,669

04/23/

Tadahiko Kohno

A-690

21069 AMGEN INCORPORATED MAIL STOP 27-4-A ONE AMGEN CENTER DRIVE

THOUSAND OAKS, CA 91320-1799



CONFIRMATION NO. 4141
FORMALITIES LETTER

OC000000008177940

Date Mailed: 05/23/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of
the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as
indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a
substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content
of the sequence listing information recorded in computer readable form is identical to the written (on paper
or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR
1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Tadahiko Kohno

Serial No.:

09/840,669

Filed:

April 23, 2001

For:

APO-AI/AII PEPTIDE DERIVATIVES

Docket No.:

A-690

ATTORNEY'S STATEMENT PURSUANT TO 37 CFR § 1.821

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

I hereby state that the paper copy and the computer readable form (CRF) of the "Sequence Listing" submitted herewith for the above-mentioned patent application are the same. The sequence listing submitted herewith contains no new matter.

Respectfully submitted,

Timothy J Gadi

Attorney for Applicants

Registration No.: 33,111 Phone: (805) 447-2688 Date: June 7, 2002

Please send all future correspondence to: U.S. Patent Operations/ TJG Dept. 4300, M/S 27-4-A AMGEN INC. One Amgen Center Drive Thousand Oaks, California 91320-1799

EXPRESS MAIL CERTIFICATE

Express Mail	man	ranemiñ
number:		

EL360693885US

Date of

ne 7,2002

I hereby certify that this paper or tee is being deposited with the United States Postal Service "Express Vall Post Office to Add above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Lynne Buchsbaum

ress Mail Fos) Office to Addressee' service under 37 C.F.R. 1.10 on the date indicated



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

radamino no

Serial No.:

09/840,669

Group Art Unit No.:

1614

Filed:

April 23, 2001

Examiner:

For:

APO-AI/AII PEPTIDE DERIVATIVES

Docket No.:

A-690

TRANSMITTAL OF DECLARATION UNDER 37 CFR §1.821
RESPONSE TO NOTICE TO COMPLY

Assistant Commissioner for Patents Washington, DC 20231

Sir:

This is in response to a "Notice to Comply" dated May 23, 2002 noting the need for a correction in the sequence listing previously provided in the above-identified application.

Enclosed herewith are: 1) an Attorney's Statement pursuant to 37 CFR §1.821 and 2) a corrected Sequence Listing to be filed in this application.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519.

Respectfully submitted,

Timothy J. Gaur Attorney for Applicant

Registration No.: 33,111 Phone: (805) 447-2688

Date: June 7, 2002

Please send all future correspondence to: US Patent Operations/ TJG Dept. 430, M/S 27-4-A AMGEN INC. One Amgen Center Drive Thousand Oaks, California 91320-1799

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number:

EL360693885US

Date of

June 7, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Lynne Buchsbarm

Single Single to Addressee Service argent 37 C.F.H. 1.10 on the date indicated